Software - Germany



Buy (old: Buy) 30.09.2024

EUR 22.00 (old: EUR 22.00)

Final H1 in line with prelims; Guidance confirmed

Topic: On Friday, VOQUZ Labs released its final H1 '24 report, in line with the preliminary results published in August. Here are the key takeaways.

H1 sales increased by 25% yoy to € 2.3m, which is in line with our estimate. A strong driver should have been the visoryQ business, which already gained traction in Q4 '23. We expect H1 visoryQ revenues to have already reached the FY '23 level of € 0.5m, as customer experience increasing time pressure regarding their SAP ERP strategy. Yet, according to management, buyers' hesitance has not yet completely subsided, still leaving room for improvement going forward.

EBITDA in **H1** came in at € 0.3m (in line with eNuW), marking a significant improvement compared to last years H1 result of € -0.5m. Alongside cost saving measures bearing fruit, which were already implemented during H2 '23, the company also benefited from an improved sales mix, i.e. a lower share of consulting orders. Those were in fact compensated by the higher margin visoryQ offering. Notably, **FCF** came in **positive with € 0.1m**, which compares to negative € 0.7m in last years period.

On this basis, management confirmed the FY guidance of 10-20% top-line growth and an EBITDA margin of 15-20%. The mid-points only imply 9.7% sales growth and a 20.6% EBITDA margin in the second half of the year (H2 '23: 28.9%). Hence, we regard the outlook as reasonable and are even at the upper end of the sales guidance range, while we remain conservative regarding our profitability outlook.

Going forward, the pending S4/HANA transformation should be seen as one of the main growth drivers at VOQUZ. The company is currently developing a Finops manager for its visoryQ solution to further improve its offering, with an intended go-to-market in Q4. Moreover, the sales partnership with PwC Germany concerning VOQUZ' remQ product should start bearing fruit in H2 (click here for more detail). According to our estimates, the TAM in Germany alone for the SAP compliance solution should be in the ballpark of € 20-25m, targeting mid- to enterprise-size customers.

To conclude, the release fully underpins our positive view on the company's prospect based on its innovative product offering. Reiterate **BUY** with an unchanged € 22 **PT** based on DCF.

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	3.9	4.7	5.3	6.3	7.9	9.6
Sales growth	31.3%	21.4%	11.3%	20.4%	24.9%	22.0%
EBITDA	1.0	0.6	0.5	1.0	1.6	2.6
Net debt (if net cash=0)	-1.0	-0.1	8.0	0.1	-0.5	-1.6
FCF	0.6	-0.3	-0.8	0.7	0.6	1.1
Net Debt/EBITDA	0.0	0.0	1.7	0.1	0.0	0.0
EPS pro forma	0.46	0.06	-0.07	0.36	0.74	1.32
EBITDA margin	24.7%	13.2%	9.3%	15.5%	20.5%	26.5%
ROCE	37.0%	10.4%	1.5%	15.1%	25.8%	39.9%
EV/sales	2.2	2.0	2.0	1.5	1.1	0.8
EV/EBITDA	8.9	14.9	21.1	9.7	5.5	3.1
PER	19.6	141.0	-129.5	25.1	12.2	6.8
Adjusted FCF yield	7.6%	2.7%	0.3%	6.6%	12.2%	21.9%


Source: Company data, NuWays, Close price as of 24.09.2024

2023

2024e

2025e

2026e



Company description

2022

2021

Source: NuWays Research

Sales (2021-26e)

10.0m

7.5m

5.0m

2.5m

0.0m

VOQUZ is a leading developer and provider of Software Asset Management (SAM) solutions with a clear focus on SAP license and authorization management.



 $\begin{array}{lll} \mbox{High/low 52 weeks } (\mbox{\in}) & 11.40 \ / \ 5.00 \\ \mbox{3m rel. performance} & -6.2\% \\ \mbox{6m rel. performance} & -13.9\% \\ \mbox{12m rel. performance} & 3.6\% \end{array}$


Market dataShare price (in €)9.00Market cap (in € m)9.5Number of shares (in m pcs)1.1Enterprise value (in € m)9.5Ø trading volume (6 months)25

Identifier						
Bloomberg	HC7 GR					
Reuters	HC7.DE					
WKN	A3CSTW					
ISIN	DE000A3CSTW4					

Key shareholders	
VOQUZ Technology GmbH	75.6%
Peter Rattey	11.4%
Free Float	13.0%

Estimates changes				
	<u>2024e</u>	2025e	<u>2026e</u>	
Sales	0%	0%	0%	
EBIT	0%	0%	0%	
EPS	0%	0%	0%	

Comment on changes



Guidance

- Sales: +10-20%
- EBITDA margin: 15-20%
 - Mid-term: > 20% EBITDA margin

Preview / Review - 30.09.2024



Financials

Profit and loss (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net sales	3.9	4.7	5.3	6.3	7.9	9.6
Sales growth	31.3%	21.4%	11.3%	20.4%	24.9%	22.0%
•	0.3	0.2	0.2	0.4	0.6	0.7
Increase/decrease in finished goods and work-in-process	4.2	5.0	5.5	6.8	8.5	10.3
Total sales	0.1	0.2	0.3	0.3	0. 5 0.4	0.4
Other operating income						
Material expenses	0.7	1.0	0.5	1.1	1.3	1.4
Personnel expenses	0.9	1.4	2.2	1.7	2.0	2.1
Other operating expenses	1.7	2.2	2.6	3.2	4.0	4.6
Total operating expenses	3.2	4.3	5.0	5.8	6.8	7.8
EBITDA	1.0	0.6	0.5	1.0	1.6	2.6
Depreciation	0.3	0.4	0.4	0.4	0.5	0.6
EBITA	0.6	0.3	0.0	0.5	1.1	2.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	0.6	0.3	0.0	0.5	1.1	2.0
Interest income	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	-0.0	0.0	0.1	0.0	0.0	0.0
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	0.0	-0.0	-0.1	0.0	0.0	0.0
Recurring pretax income from continuing operations	0.6	0.3	-0.0	0.5	1.1	2.0
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	0.6	0.3	-0.0	0.5	1.1	2.0
Income tax expense	0.1	0.2	0.1	0.2	0.3	0.6
Net income from continuing operations	0.5	0.1	-0.1	0.4	0.8	1.4
ncome from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	0.5	0.1	-0.1	0.4	0.8	1.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (reported)	0.5	0.1	-0.1	0.4	0.8	1.4
Average number of shares	1.0	1.0	1.0	1.0	1.0	1.0
EPS reported	0.46	0.06	-0.07	0.36	0.74	1.32
Profit and loss (common size)	2021	2022	2023	2024e	2025e	2026
Net sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales growth	31.3%	21.4%	11.3%	20.4%	24.9%	22.0%
Increase/decrease in finished goods and work-in-process	7.1%	5.2%	4.0%	7.0%	7.0%	7.0%
Total sales	107.1%	105.2%	104.0%	107.0%	107.0%	107.0%
Other operating income	2.2%	3.7%	5.8%	4.0%	4.5%	4.5%
Material expenses	17.8%	20.3%	10.2%	18.0%	16.0%	15.0%
Personnel expenses	23.0%	28.9%	41.2%	27.5%	25.0%	22.0%
Other operating expenses	43.9%	46.6%	49.1%	50.0%	50.0%	48.0%
Total operating expenses	82.4%	92.0%	94.7%	91.5%	86.5%	80.5%
EBITDA	24.7%	13.2%	9.3%	15.5%	20.5%	26.5%
Depreciation	8.7%	7.7%	8.4%	7.0%	6.5%	6.0%
EBITA	15.9%	5.5%	0.8%	8.5%	14.0%	20.5%
Amortisation of goodwill	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Amortisation of intangible assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impairment charges	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT (inc revaluation net)	15.9%	5.5%	0.8%	8.5%	14.0%	20.5%
` ,						
Interest income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
nterest expenses	-0.2%	0.0%	1.2%	0.0%	0.0%	0.0%
Investment income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Financial result	0.2%	neg.	neg.	0.0%	0.0%	0.0%
Recurring pretax income from continuing operations	16.1%	5.5%	-0.3%	8.5%	14.0%	20.5%
Extraordinary income/loss	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings before taxes	16.1%	5.5%	-0.3%	8.5%	14.0%	20.5%
Tax rate	22.8%	74.2%	-305.6%	30.0%	30.0%	30.0%
Net income from continuing operations	12.4%	1.4%	-1.4%	6.0%	9.8%	14.4%
not moone non community operations						

Net profit (reported)
Source: Company data, NuWays

Net income

Minority interest

Income from discontinued operations (net of tax)

NuWays AG 2

0.0%

-1.4%

0.0%

-1.4%

0.0%

6.0%

0.0%

6.0%

0.0%

9.8%

0.0%

9.8%

0.0%

14.4%

0.0%

14.4%

0.0%

1.4%

0.0%

1.4%

0.0%

12.4%

0.0%

12.4%

Preview / Review - 30.09.2024



	0004	0000	0000	0004	0005	0000
Balance sheet (EUR m)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	1.5	1.5	1.8	1.8	1.8	1.8
Property, plant and equipment	0.0	0.0	0.0	0.0	0.0	0.0
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0
FIXED ASSETS	1.5	1.5	1.8	1.8	1.8	1.8
Inventories	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable	1.8	2.5	3.7	3.5	3.9	4.5
Other assets and short-term financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Liquid assets	1.0	0.3	0.1	0.8	1.4	1.6
Deferred taxes	0.0	0.0	0.1	0.1	0.1	0.0
Deferred charges and prepaid expenses	0.1	0.1	0.1	0.1	0.1	0.0
CURRENT ASSETS	2.9	3.0	3.9	4.5	5.5	6.1
TOTAL ASSETS	4.4	4.5	5.8	6.3	7.3	7.9
SHAREHOLDERS EQUITY	1.9	2.0	1.9	2.5	3.4	4.7
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0
Long-term liabilities to banks	0.0	0.2	0.9	0.9	0.9	0.0
Bonds (long-term)	0.0	0.0	0.0	0.0	0.0	0.0
other interest-bearing liabilities	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0
Other provisions and accrued liabilities	0.3	0.2	0.2	0.2	0.2	0.2
NON-CURRENT LIABILITIES	0.3	0.4	1.1	1.1	1.1	0.2
Short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.4	0.5	0.8	0.9	1.0	1.2
Advance payments received on orders	0.0	0.0	0.2	0.0	0.0	0.0
Accrued taxes	0.0	0.3	0.3	0.3	0.3	0.3
Other liabilities (incl. from lease and rental contracts)	0.8	0.4	0.5	0.5	0.5	0.5
Deferred taxes	0.0	0.4	0.3	0.3	0.3	0.3
Deferred income	0.2	0.2	0.8	0.8	0.8	0.8
CURRENT LIABILITIES	2.1	2.1	2.8	2.7	2.8	3.1
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	4.4	4.5	5.8	6.3	7.3	7.9
Delence sheet (semmen size)	2021	2022	2022	2024e	2025e	2026e
Balance sheet (common size) Intangible assets	34.1%	33.3%	2023 31.4%	28.8%	24.9%	20266
Property, plant and equipment	0.0%	0.1%	0.5%	0.5%	0.4%	0.4%
Financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%
FIXED ASSETS	34.2%	33.4%	31.9%	29.3%	25.3%	23.3%
Inventories	1.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts receivable	40.3%	56.7%	63.8%	54.9%	53.3%	56.7%
Other assets and short-term financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Liquid assets	21.8%	6.2%	1.1%	12.8%	18.9%	20.0%
Deferred taxes	0.8%	0.8%	1.1%	1.0%	0.9%	0.0%
Deferred charges and prepaid expenses	1.7%	2.7%	2.1%	1.9%	1.7%	0.0%
CURRENT ASSETS	65.8%	66.6%	68.1%	70.7%	74.7%	76.7%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
CHARELIOL DEDO FOLIEV	44.001	44.00/	00.00/	00.00/	40.00/	F0 051
SHAREHOLDERS EQUITY MINODITY INTEREST	44.3%	44.3%	33.2%	39.3%	46.2%	58.8%
MINORITY INTEREST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Long-term liabilities to banks	0.0%	3.8%	15.5%	14.3%	12.3%	0.0%
Bonds (long-term)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
other interest-bearing liabilities	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other provisions and accrued liabilities	7.5%	4.5%	2.8%	2.8%	2.7%	2.7%
NON-CURRENT LIABILITIES	7.5%	8.3%	18.3%	17.2%	15.0%	2.7%
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	8.3%	11.9%	13.6%	13.8%	13.3%	15.0%
Advance payments received on orders	0.5%	0.0%	2.7%	0.0%	0.0%	0.0%
Accrued taxes	3.2%	6.1%	5.0%	4.6%	4.0%	3.6%
Other liabilities (incl. from lease and rental contracts)	18.9%	8.4%	8.0%	7.4%	6.3%	5.8%
Deferred taxes	5.2%	5.3%	5.2%	4.8%	4.1%	3.8%
Deferred income	12.1%	15.7%	14.0%	12.9%	11.1%	10.3%
CURRENT LIABILITIES	48.1%	47.4%	48.5%	43.5%	38.8%	38.5%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Preview / Review - 30.09.2024



Cash flow statement (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net profit/loss	0.5	0.1	-0.1	0.4	0.8	1.4
Depreciation of fixed assets (incl. leases)	0.3	0.4	0.4	0.4	0.5	0.6
Amortisation of goodwill & intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Other costs affecting income / expenses	0.0	0.2	0.5	0.0	0.0	0.0
Cash flow from operating activities	0.4	-0.1	-0.4	0.9	0.8	1.3
Increase/decrease in inventory	0.5	0.0	0.0	0.0	0.0	0.0
Increase/decrease in accounts receivable	-0.8	-0.8	-1.2	0.2	-0.4	-0.6
Increase/decrease in accounts payable	0.1	0.2	0.3	0.1	0.1	0.2
Increase/decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in working capital	-0.2	-0.6	-0.9	0.3	-0.3	-0.4
Cash flow from operating activities	0.6	0.1	-0.0	1.1	1.0	1.6
CAPEX	0.0	0.4	0.8	0.4	0.4	0.5
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.2	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-0.2	-0.4	-0.8	-0.4	-0.4	-0.5
Cash flow before financing	0.4	-0.3	-0.8	0.7	0.6	1.1
Increase/decrease in debt position	0.0	0.2	0.6	0.0	0.0	-0.9
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.4	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	-0.6	0.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	0.4	-0.4	0.6	0.0	0.0	-0.9
Increase/decrease in liquid assets	0.8	-0.7	-0.2	0.7	0.6	0.2
Liquid assets at end of period	1.0	0.3	0.1	0.8	1.4	1.6
<u> </u>			-			
Key ratios (EUR m)	2021	2022	2023	2024e	2025e	2026e
P&L growth analysis						
Sales growth	31.3%	21.4%	11.3%	20.4%	24.9%	22.0%
EBITDA growth	44.8%	-34.9%	-21.9%	101.0%	65.2%	57.7%
EBIT growth	37.2%	-57.9%	-83.1%	1122.7%	105.7%	78.6%
EPS growth	n.a.	-86.1%	-209.0%	-615.9%	105.7%	78.6%
Efficiency						
Sales per employee	129.7	135.0	122.3	131.0	148.8	165.0
EBITDA per employee	32.0	17.9	11.3	20.3	30.5	43.7
No. employees (average)	30	35	43	48	53	58
Balance sheet analysis						
Avg. working capital / sales	26.5%	28.8%	39.7%	36.4%	35.9%	30.6%
Inventory turnover (sales/inventory)	77.8	n.a.	80.0	80.0	80.0	80.0
Accounts receivable turnover	164.9	196.0	256.8	200.0	180.0	170.0
Accounts payable turnover	34.0	41.2	54.8	50.0	45.0	45.0
Cash flow analysis						
Free cash flow	0.6	-0.3	-0.8	0.7	0.6	1.1
Free cash flow/sales	14.8%	-6.2%	-15.9%	11.8%	7.2%	11.4%
FCF / net profit	119.3%	neg.	1147.9%	198.6%	73.6%	79.6%
Capex / sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Solvency						
Net debt	-1.0	-0.1	0.8	0.1	-0.5	-1.6
Net Debt/EBITDA	0.0	0.0	1.7	0.1	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	-21.8%	0.6%	6.9%	0.0%	0.0%	0.0%
Returns						
ROCE	37.0%	10.4%	1.5%	15.1%	25.8%	39.9%
ROE	25.0%	3.4%	-3.8%	15.3%	22.9%	29.7%
Adjusted FCF yield	7.6%	2.7%	0.3%	6.6%	12.2%	21.9%
Dividend yield	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%	-0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	0.46	0.06	-0.07	0.36	0.74	1.32
Average number of shares	1.0	1.0	1.0	1.0	1.0	1.02
Valuation ratios	1.0	1.0	1.5	1.0	1.0	1.5
P/BV	4.9	4.8	4.9	3.8	2.8	2.0
EV/sales	2.2	2.0	2.0	1.5	1.1	0.8
EV/BITDA						
	ЯG	14 4	/11	97	יר א	.5.1
	8.9 13.7	14.9 35.8	21.1 233.8	9.7 17.7	5.5 8 1	3.1 4.0
EV/EBIT Source: Company data, NuWays	8.9 13.7	14.9 35.8	233.8	9.7 17.7	5.5 8.1	4.0

Preview / Review - 30.09.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
VOQUZ Labs AG	2,8

Historical target price	and rating changes for VOQL	JZ Labs AG			
Company	Date	Analyst	Rating	Target Price	Close
VOQUZ Labs AG	06.03.2024	Sennewald, Philipp	Buy	EUR 22.00	EUR 8.50
	20.11.2023	Sennewald, Philipp	Buy	EUR 20.00	EUR 7.45

Preview / Review - 30.09.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 30/09/2024 07:15 AM

Date of publication dissemination: 30/09/2024 07:16 AM

Preview / Review - 30.09.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



LinkedIn

